Clinical trial
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
NCT01439568
Study timeline
Study start (unknown)2011-09-01Date precision: month
Registry last updated2019-07-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
LY2510924DRUG
CarboplatinDRUG · verified · RxNorm: carboplatin
EtoposideDRUG · verified · RxNorm: etoposide
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
ChicagoIllinois, United States1NashvilleTennessee, United States1CincinnatiOhio, United States1OrlandoFlorida, United States1DenverColorado, United States1OmahaNebraska, United States1RichmondVirginia, United States1BethesdaMaryland, United States1MemphisTennessee, United States1GreenvilleSouth Carolina, United States1Fort WorthTexas, United States1Fort MyersFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01439568 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.